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Abstract 
Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in 
neurological disorders and there are no treatment guidelines. However, as a rapidly acting, targeted 
therapy with growing evidence of efficacy and tolerability in several neuro inflammatory disorders, it 
is an attractive alternative to conventional immunomodulatory medications. This practical review 
aims to explain the basic principles of B-cell depletion with therapeutic monoclonal antibodies.  We 
present the evidence for using rituximab in neurological diseases, and describe the practical aspects 
of prescribing, including dosing, monitoring, safety, treatment failure and its use in special 
circumstances such as coexisting viral hepatitis, pregnancy and lactation. We provide an 
administration guide, checklist and patient information leaflet, which can be adapted for local use. 
Finally, we review the safety data of rituximab and ocrelizumab (a newer and recently licensed B-
cell-depleting therapy for multiple sclerosis) and suggest monitoring and risk reduction strategies. 
 
Introduction 
This article covers both the practical aspects of prescribing rituximab and some of the basic 
principles of B-cell depletion with monoclonal antibodies, which are relevant to neurologists. Those 
seeking an administration guide for rituximab, or a rapid overview of the indications and supporting 
evidence, expected side-effects or specific prescribing circumstances, should skip to the relevant 
tables towards the end of the article. We have provided an example of a patient information sheet 
and an administration checklist, which are available as online supplementary material 1 and 2. 
 
B-cell function and role in neurological disease 
B-cells secrete antibodies, present antigen and regulate the immune response by producing pro 
inflammatory and anti-inflammatory cytokines. Only 2.5% of the total B-cell population is within the 
peripheral circulation, made up predominantly of naïve mature B-cells and memory B-cells; the rest 
are in bone marrow and lymphoid tissue.1 Antibodies may be of any immunoglobulin class (G, M, A, 
D or E) or subclass (eg, IgG1–4), each of which have differing functions. Examples of disorders in 
which autoantibodies are almost certainly pathogenic include myasthenia gravis with acetylcholine 
receptor (AChR) antibodies (usually 
IgG1 or IgG3) or muscle-specific tyrosine kinase (MuSK) antibodies (IgG4), neuromyelitis optica 
spectrum disorders (NMOSD) with antibodies against the aquaporin-4 water channel (mainly IgG1), 
and autoimmune encephalitis with antibodies to the N-methyl-D-aspartate receptor (NMDAR) 
(mainly IgG1) or leucine-rich glioma inactivated-1 (LGI1) (mainly IgG4). B-cells also play a crucial role 
in multiple sclerosis (MS) pathogenesis, evidenced by cerebrospinal fluid oligoclonal IgG bands, 
meningeal-based ectopic B-cell follicles adjacent to areas of focal cortical demyelination2 and the 
efficacy of B-cell-depleting therapies to treat MS. 
 
B-cell surface markers 
CD19 and CD20 are B-cell transmembrane proteins. They can be used as targets for drugs and as 
surface markers (in flow cytometry to quantify B-cell populations and assess treatment response). 
CD19 is expressed more widely throughout B-cell development than CD20 but both markers are 
absent on long-lived plasma cells (figure 1). In healthy adults CD19+ or CD20+ B-cells comprise 12%–
22% of the total circulating lymphocyte population (absolute reference range is 50–500 cells/mm3). 
CD27 is expressed by memory B-cells and certain other immune cell types. The combination of CD19 
and CD27 is specific to memory B-cells. This subset of long-lived B-cells, capable of rapid 
differentiation into high-affinity plasma cells following repeated antigen exposure, may be an 
important target in the treatment of autoimmune neurological disease.3 4 
 
 
 
Figure 1 Stages of B-cell development and expression of B-cell surface markers. Pluripotent 
haematopoietic stem cells develop into naïve mature B cells in the bone marrow. They then migrate 
to secondary lymphoid organs (spleen and lymph nodes), where they are activated by antigens in 
circulating lymph and mature into memory B-cells or plasmablasts. Memory B-cells either circulate in 
the bloodstream or remain in germinal centres, while plasmablasts mature to antibody-secreting 
plasma cells that reside in the bone marrow or lymphoid tissue. CD20 (yellow triangles) appears at 
the immature B-cell stage and is lost at the plasmablast stage.  Most plasmablasts and nearly all 
plasma cells (which produce the vast majority of antibodies) do not express CD20. CD19 (red 
triangles) has wider expression from the pro-B-cell stage through to plasmablasts and a proportion 
of plasma cells, but not terminally differentiated plasma cells. 
 
B-cell-depleting monoclonal antibodies 
Monoclonal antibodies are immunoglobulins produced by a single clone of hybridoma cells (antigen- 
specific plasma cells fused with myeloma cells). 
They bind via their two identical fragment antigen binding (Fab) domains to a single epitope and 
activate the immune system via their fragment crystallisable (Fc) domain. Cells expressing that 
epitope are killed, therefore allowing highly targeted immunotherapy for a variety of neoplastic and 
autoimmune diseases. Available B-cell-depleting monoclonal antibodies have Fab domains targeted 
to CD20 or CD19, and so selectively deplete the circulating B-cell population, with the exception of 
mature antibody-secreting plasma cells. 
figure 2 shows those used in treating neuroinflammatory diseases. 
Rituximab was the first anti-CD20 monoclonal antibody to be approved (1997) for treating B-cell 
lymphomas. It has since been licensed to treat refractory rheumatoid arthritis and antineutrophil 
cytoplasmic antibody (ANCA)-associated vasculitis. Unlicensed use for neuroinflammatory disease is 
growing. 
Rituximab is a first-generation, chimeric monoclonal antibody made by fusing a murine (rodent) Fab 
domain with a human Fc domain (‘chimeric’ is from the mythological Chimera—a monstrous 
firebreathing hybrid creature, part lion and part goat). 
The Fc domain activates various immune mechanisms, as shown in figure 3. Ninety per cent of 
circulating B-cells are killed within 3 days of the first infusion of rituximab. Reduction of pathogenic 
antibody titres correlates with efficacy in some disorders. However, rituximab probably affects the 
whole spectrum of B-cell function, and secondary changes in T-cell function, such as induction of 
immunoregulatory T cells, may be important in some neuroinflammatory disorders. Sparing of 
CD20negative long-lived plasma cells is 
hoped to preserve lasting humoral immunity. 
Compared with first-generation monoclonal antibodies, second-generation monoclonal antibodies 
have improved Fab domains, often humanised or fully human, which improve B cell killing and 
tolerability (figure 2). Ocrelizumab (humanised) was recently approved to treat relapsing and 
progressive MS. Ofatumumab, a fully human monoclonal antibody given by once monthly 
subcutaneous injection, is in clinical trials. Third-generation monoclonal antibodies have been 
further engineered to improve their Fc-mediated immune functions or half-life. Ublituximab (TG-
1101), a rapidly infusible chimeric glycol engineered monoclonal antibody, is also being trialled in MS 
currently. 
Anti-CD19 B-cell-depleting therapies may be more effective (and potentially have higher risks) than 
anti- CD20 therapies due to the broader expression of CD19 throughout B-cell development, 
including the plasmablast phase (figure 1). Inebilizumab (MEDI- 551) is in a phase 3 trial in NMOSD.5 
 
 
 
Figure 2 B-cell-depleting monoclonal antibodies in neurology. mAb, monoclonal antibody; MS, 
multiple sclerosis; NMOSD, neuromyelitis optica  spectrum disorder. 
 
Biosimilars 
Most monoclonal antibodies are costly. However, once the original drug patent expires, cheaper, 
copy versions—‘biosimilars’—become available. Competing companies do not have access to the 
original molecular clone, cell bank or exact manufacturing process, which may result in slight 
differences to these complex molecular structures. Therefore, biosimilars are not truly ‘generic’. To 
gain a licence, biosimilars must be shown to be highly similar in structure, purity and biological 
activity to the original monoclonal antibody; however, it is not necessary to repeat clinical trials for 
each indication. Rituximab’s patent expired in 2016 and the European Medicines Agency (EMA) has 
approved two biosimilars, Truxima and Rixathon. The dosing and administration protocols are 
identical. British National Formulary prices are currently £1746 for MabThera 1 g (the original form 
of rituximab) vs £1572 for Truxima or Rixathon.6 However, prices to National Health Service 
(NHS) hospitals vary substantially according to regional contracts and discussion with the hospital 
pharmacy department is advised. Patients should be informed of the switch and monitored to 
ensure that tolerability and side effects remain unchanged. 
 
 
 
Figure 3 Rituximab depletes CD20+ B-cells via three different mechanisms: (1) antibody-
dependent cellular cytotoxicity mediated by Fc receptors on the surface of natural killer 
cells, granulocytes and macrophages; (2) complement-dependent cytotoxicity; (3) induction 
of apoptosis. 
 
Indications and evidence for rituximab in neurology 
An understanding of the evidence for rituximab in neuroinflammatory disorders (see table 1 for a 
briefer summary) should inform off-license prescribing. 
Multiple sclerosis 
With a choice of licensed disease-modifying therapies supported by phase III randomised controlled 
trials, use of rituximab in the UK for MS is rare. However, there is evidence suggesting efficacy, and it 
may be an option in occasional cases (especially if licensed comorbidities, such as active rheumatoid 
arthritis, facilitate funding). Phase I and II trials of rituximab in relapsing– remitting MS met their 
primary endpoints.7–9 A large 96-week multicentre randomised controlled trial in primary 
progressive MS failed to demonstrate a delay to confirmed disease progression, but subgroup 
analysis showed a benefit in younger patients, particularly with inflammatory lesions.10 Trials in MS 
then ceased, probably due to the impending expiration of rituximab’s patent and the emergence of 
newer B-cell-depleting therapies from the same manufacturer. Sweden is the biggest off-licence 
prescriber of rituximab for all forms of MS and has published class IV evidence of safety and efficacy 
in a large multicentre cohort (n=822).11 The dose used is 500–1000 mg 6–12 monthly. A recent real-
world retrospective comparative study showed efficacy in relapsing–remitting MS comparable to 
natalizumab and fingolimod, and significantly better than injectable disease-modifying therapies and 
dimethyl fumarate. Rituximab was superior to all drugs in terms of discontinuation rate.12 Although 
this is relatively low-quality evidence, there is a clear indication that rituximab is an effective 
treatment for MS, which would be expected in light of the recent positive randomised controlled 
trials for ocrelizumab. 
 
Neuromyelitis optica spectrum disorders 
No immunosuppressive therapy in NMOSD is yet validated by a high-quality randomised controlled 
trial, though there are three such trials ongoing. Rituximab use is supported by numerous, 
predominantly retrospective, case series amounting to over 400 patients and showing consistent 
reductions in annualised relapse rate. There are various dosing strategies in use, which we discuss 
later in ‘dosing and monitoring’. A recent meta-analysis calculated a mean reduction in relapse rate 
of 79%.13 As such, rituximab currently has the best evidence of any immunotherapy used in 
NMOSD, but due to its relatively high cost, it remains second-line therapy for patients in the UK. It is 
available for patients who have relapsed despite adequate treatment with azathioprine or 
mycophenolate mofetil combined with low-dose prednisolone.14 Funding can be obtained through 
the Specialised NHS England Service for NMOSD ( www. nmouk. nhs. uk). 
 
Autoimmune encephalitis 
As most autoimmune encephalitis is monophasic, the role of rituximab is usually as a second-line 
acute therapy (single course) to maximise neurological recovery, rather than as a long-term 
maintenance treatment (as with MS/NMOSD). The most commonly used dosing regimen is 375 
mg/m2 weekly for four doses. Limited retrospective evidence supports its use when there has been 
an inadequate response to intravenous corticosteroids, plasma exchange and intravenous 
immunoglobulin. There is no evidence to compare the effects of individual immunotherapies in 
autoimmune encephalitis, so it is not possible to ascribe therapeutic benefits solely to rituximab. 
However, its rapid onset of action, established efficacy in other with short-term use make it an 
attractive option. The major study supporting rituximab use in autoimmune encephalitis is a 
retrospective comparison of outcomes in 161 patients. Functional improvement measured by 
modified Rankin Scale occurred more frequently in the rituximab-treated group, regardless of 
antibody status).15 
There is additional evidence specifically for anti-NMDAR encephalitis, the most common subtype of 
autoimmune encephalitis. A large prospective cohort study (n=577) found that 78% of patients who 
failed first-line and received second-line immunotherapy (rituximab and/or cyclophosphamide) had 
a good outcome at 24 months, compared with 55% of patients who failed first-line and did not 
receive second-line therapy.16 A study of rituximab in paediatric neuroinflammatory disease 
included 44 patients with anti-NMDAR encephalitis. Ninety-seven per cent of these patients had 
some benefit from second-line rituximab therapy, especially when given early.17 In light of these 
studies, a UK clinical commissioning policy, published in March 2018, agreed to fund rituximab 
routinely for adults and children with anti-NMDAR encephalitis who have responded inadequately to 
first-line therapy (failure to improve by two or more points on the modified Rankin Scale by 4 weeks 
from starting first-line treatment or by 6 weeks from symptom onset).18 
 
 
  
 
Figure 4 Rituximab administration guide. Italicised points reflect our personal practice rather than 
established recommendations. HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human 
immunodeficiency virus; NMDAR, N-methyl-D-aspartate receptor; NMOSD, neuromyelitis optica 
spectrum disorders; TB, tuberculosis; VZV, varicella zoster virus. 
Evidence for autoimmune encephalitis with less common antibodies is limited to case reports and 
small case series, which are frequently confounded by coadministration of multiple 
immunotherapies. For example, there are two case series reporting outcomes after rituximab in 
seven patients with anti-LGI1 encephalitis. Three patients (43%) had good outcomes and one patient 
had a possible response.19 20 The emerging theme in autoimmune encephalitis, irrespective of 
antibody status, is that early and aggressive immunotherapy is beneficial. It seems plausible that 
rituximab, or similar B-cell-depleting therapies, will increasingly form part of immunotherapy 
algorithms. Primary angiitis of the central nervous system High-dose corticosteroids with or without 
cyclophosphamide form the mainstay of treatment for this rare condition.21 Favourable outcomes 
with rituximab are reported in two small case series, in which 2/2 and 6/7 patients appeared to 
respond.22 23 There are additional case reports describing its use.24 
 
ANCA-associated vasculitis 
ANCA-associated vasculitis occasionally presents to the neurologist, for example, with mononeuritis 
multiplex, but is likely to be comanaged with other vasculitis experts. Rituximab is licensed and 
recommended by recent European Guidelines for organ or life-threatening disease.25 This follows 
two randomised controlled trials, in which rituximab (375 mg/m2 weekly for four doses) was non-
inferior to cyclophosphamide for inducing remission.26 27 It may be more effective than 
cyclophosphamide for relapsing disease.27 NHS England will fund rituximab where 
cyclophosphamide has failed or is contraindicated 
(eg, patients who wish to preserve their reproductive potential).28 
  
Stiff-person syndrome 
Although some case reports suggested a possible benefit of rituximab for stiff-person syndrome,29–
31 a single small double-blind randomised controlled trial (n=24) found no significant changes in any 
outcome measures after 6 months of rituximab treatment.32 
 
Immune-mediated peripheral neuropathies A UK clinical commissioning policy, published in 
December 2017, reviewed the evidence for rituximab to treat chronic inflammatory demyelinating 
polyradiculoneuropathy (CIDP), multifocal motor neuropathy, non-systemic vasculitic neuropathy 
and IgM paraprotein-associated demyelinating neuropathy with antibodies to myelin-associated 
glycoprotein (anti-MAG neuropathy). It concluded that there is insufficient evidence to make 
rituximab routinely available for these disorders.33 However, there may be circumstances in which 
rituximab could help, as discussed below. Most studies have used 375 mg/m2 weekly for 4 weeks. 
Rituximab has been used in CIDP following inadequate response to conventional therapy 
(corticosteroids, intravenous immunoglobulin and plasma exchange). A Cochrane review (2013) 
identified 17 published CIDP cases treated with rituximab, of which 12 (71%) improved after 
treatment.34 The largest series has 10 patients, of whom six (60%) improved.35 In a multicentre 
retrospective analysis, 18/110 (16.4%) refractory CIDP cases received rituximab. The response rate 
(improvement in modified Rankin Scale score by at least 1 point) was 33%—comparable to 
azathioprine or cyclophosphamide.36 There was a recent report of marked improvement following 
rituximab in patients with CIDP with IgG4 antibodies against paranodal proteins (anti-neurofascin 
155/CNTN1). These cases account for less than 10% of all patients with CIDP but they are often 
relatively resistant to intravenous immunoglobulin and corticosteroids, highlighting the importance 
of serological testing and suggesting a potential role for rituximab in a subset of patients with CIDP 
that needs further exploration.37 38  
Data for rituximab in multifocal motor neuropathy are limited to small case series and are 
conflicting. Intravenous immunoglobulin is the mainstay of therapy. When rituximab was used as 
monotherapy in seven patients in two separate observational studies, all showed some 
improvement in muscle strength.39 40 When given as an adjunct to intravenous immunoglobulin in 
a small open label trial (n=6), there was no significant change in motor function or required dose.41 
In two further cases, one patient reduced and one increased their intravenous immunoglobulin 
requirement.42 
Non-systemic vasculitic neuropathy is a peripheral nerve vasculitis in the absence of clinical or 
laboratory evidence of systemic vasculitis. The Peripheral Nerve Society guideline (2010) lists 
rituximab as an unproven treatment option, favouring high-dose corticosteroids and escalation to 
cyclophosphamide if needed.43 Rituximab could possibly be considered on an individual funding 
basis in patients with refractory non-systemic vasculitic neuropathy, on the basis of its efficacy in 
ANCA-associated vasculitis.44 
Two placebo-controlled trials of rituximab for anti-MAG neuropathy showed marginal benefits. In 
the first study, 4/13 (31%) rituximab-treated patients improved by one or more Inflammatory 
Neuropathy Course and Treatment (INCAT) score compared with 0/13 placebo-treated patients 
(p=0.036).45 In the second study (n=54), there was no significant difference in the absolute INCAT 
sensory score between the groups (negative primary outcome), but the number of patients with 
improvement in INCAT disability score was higher in the rituximab-treated group.46 Several 
prospective observational studies report improvements in roughly half to two-thirds of patients.47–
50 
 
Myasthenia gravis 
International consensus guidelines (2016) advise that ‘rituximab should be considered as an early 
therapeutic option in patients with MuSK-associated myasthenia gravis who have an unsatisfactory 
response to initial immunotherapy.’51 A formal consensus could not be reached for AChR-associated 
myasthenia gravis. Several predominantly retrospective, observational studies and two systematic 
reviews have investigated rituximab as an acute therapy (usually a single course with variable 
dosing) for refractory myasthenia gravis (persistent weakness or need for high-dose corticosteroids 
despite conventional immunosuppression). 
Despite many case series being shared between the systematic reviews, the reported response rates 
in AChR-associated myasthenia gravis are discordant, with 30%–80% of patients achieving a 
Myasthenia Gravis Foundation of America post-intervention status 
(MGFA-PIS) of ‘minimal manifestations or better’ following rituximab.52 53 This may be explained by 
variability in patient selection, inclusion of many ‘burnt out’, unresponsive cases and inclusion of 
cases where MGFA-PIS was not used as an outcome measure in the original report. Response did not 
correlate well with AChR antibody titres.53 Two ongoing randomised controlled trials may help 
better define the efficacy of rituximab in AChR-associated myasthenia gravis in the near future. 
In comparison, response rates in MuSK-associated myasthenia gravis were high (72%–89%) in both 
reviews.52 53 A further blinded prospective review found 67% of rituximab-treated patients 
obtained MGFA-PIS of ‘minimal manifestations or better’ versus 26% of controls.54 The benefit of 
rituximab in MuSK-associated myasthenia gravis appears to be more prolonged and correlates better 
with antibody titres.53 55 MuSK antibodies are of the IgG4 subtype whereas AChR antibodies are of 
the IgG1/3 subtype. The superior efficacy of rituximab may therefore be explained by selective 
depletion of short-lived IgG4-producing 
B-cells.55 
 
Dosing and monitoring of rituximab 
Rituximab is given by intravenous infusion over 3–6 hours. A solution for subcutaneous injection is 
available but is not used in neurology and therefore will not be discussed in this review. There is no 
validated dosing strategy for rituximab in neuroinflammatory disease and there is great 
heterogeneity in the literature. Figure 4 is a suggested administration guide. The two most common 
dosing regimens are either 375 mg/m2 body surface area given once weekly for 4 weeks (adopted 
from haemato-oncology) or two infusions of 500–1000 mg given a fortnight apart (adopted from 
clinical trials in rheumatoid arthritis). Following two 1000 mg infusions, the mean half-life of 
rituximab is 20.8 days (range 8.58–35.9 days).56 
In rheumatoid arthritis there is no significant difference in the clinical responses after high-dose 
(2×1000 mg) and lower dose (2×500 mg) rituximab regimens.57 The clinical response correlates with 
the degree of B-cell depletion, not the rituximab dose used.58 The same is likely to be true in 
neuroinflammatory disease. Doses as low as 100 mg weekly for 3–4 weeks have been used 
successfully in small series of patients with MS, NMOSD and anti-NMDAR encephalitis.59–62 Near 
complete B-cell depletion occurs within a fortnight of infusion and usually persists for 6–12 months. 
Therefore, where maintenance treatment is planned, repeated courses have commonly been given 
at regular six monthly intervals. However, patients vary significantly in both the initial rituximab dose 
required to achieve B-cell depletion and the time to B-cell repopulation. 
In a study of patients with NMOSD, 17% repopulated their B-cells before 6 months.63 Prolonged B-
cell depletion lasting over 3 years following a single dose of rituximab is also reported.64 This makes 
a case for monitoring and retreating according to B-cell repopulation, which will identify ‘early 
repopulators’ at risk of disease relapse, and limit overtreatment of patients with sustained B-cell 
depletion, thereby preventing complications and reducing cost. 
Although rituximab is an anti-CD20 antibody, quantification of CD19+ cells using flow cytometry is 
the preferred method for monitoring B-cell depletion and repopulation. This is because rituximab 
still present in serum could block binding of fluorophore-labelled anti-CD20 antibodies used in flow 
cytometry, thereby interfering with the detection of B-cells. 
Among the several relapsing illnesses that may benefit from rituximab, relapses from NMOSD pose 
the highest risk of permanent disability. However, the critical threshold of B-cells in the measurable 
peripheral circulation that is associated with NMOSD relapse is undetermined and is likely to vary 
with the disease and individual. Neurologists have retreated when the CD19+ B-cell count becomes 
detectable65 or more than 0.1% of total circulating lymphocyte count.66 Some measure the much 
smaller memory B-cell (CD19+/CD27+) population (see figure 4 — option 2).4 67 Switching from six 
monthly infusions to memory B-cell-monitored treatment reduces cumulative rituximab dose 
without apparent loss of efficacy.68 However, standardisation of flow cytometry techniques and 
inaccuracy when quantifying very small cell populations can pose problems.69 In the UK NMO 
Service we use monthly CD19+ B-cell monitoring and have found 1% (an arbitrary value based on 
clinician experience) to be an acceptable cut-off for retreatment for the majority of patients.70 In 
those who relapse with a detectable B-cell count below 1%, retreatment aiming for complete 
suppression is suggested before considering treatment failure and switching immunotherapy. 
 
Treatment failure 
Where treatment failure is suspected, we advise excluding alternative possibilities, such as 
intercurrent infection, and ensuring that B-cell depletion is adequate by checking a peripheral blood 
CD19+ B-cell count. Possible reasons for treatment failure include the following: 
 
Lack of efficacy of B-cell depletion 
In a large NMOSD cohort (n=100), nine patients (9%) experienced relapses despite CD19+/CD27+ 
memory B-cell depletion within target range.71 NMOSD relapses occurring on rituximab are 
generally milder than those occurring off treatment. Non-circulating B-cells in lymphoid tissues (ie, 
most of the total body B-cell population) and long-lived plasma cells are not thought to be depleted 
by rituximab and may have a role in breakthrough disease. 
  
Early relapses/delayed therapeutic onset 
Early NMOSD relapses can follow rituximab induction therapy.4 72 73 This may be due to 
incomplete B-cell depletion. Alternatively, initial B-cell depletion may induce release of systemic B-
cell activating factor, promoting autoantibody production by plasma cells, and ‘leading to a transient 
rise’ in antibody titre and early relapses.74 
 
Incomplete B-cell depletion/early repopulators 
Genetic factors may explain why some patients do not maintain adequate B-cell depletion. These 
include polymorphisms in the B-cell activating factor gene or in the Fc gamma receptor 3A gene 
expressed by the effector cells that mediate B-cell killing (figure 3).71 75 Another hypothetical 
reason might be the development of antidrug antibodies. 
 
Antidrug antibodies  
The efficacy of some monoclonal antibodies is reduced by antidrug antibodies, for example, anti-
tumour necrosis factor agents. Fab binding could have a neutralising effect and Fc binding may 
increase drug clearance. However, the role of anti-drug antibodies in rituximab treatment failure is 
uncertain. They were identified in a third of patients with MS treated with rituximab.76 They may 
have a greater effect in patients on low-dose rituximab (100 mg infusions)77 but higher, standard 
doses probably overcome the effects of antidrug antibodies.76 78 Outside of trials, detection of 
antidrug antibodies can be technically difficult, poorly standardised and is hard to obtain for routine 
use. 
 
Combination with other immunosuppressive medications 
Due to the risk of early relapse after rituximab initiation, some neurologists continue moderate-dose 
prednisolone (usually 10–20 mg daily) for 4–12 weeks in NMOSD. The decision to continue 
corticosteroids depends on the condition being treated and individual patient factors. 
Combination with other immunosuppressive medications can be considered in some circumstances 
but must be balanced against the risk of immunocompromise.  We generally reserve combination 
therapy for refractory disease. In treating rheumatoid arthritis, rituximab is often combined with 
methotrexate or leflunomide but there is little evidence to guide practice in neuroinflammatory 
disease. 
 
Risks and adverse events 
The efficacy of rituximab and current safety data support its use, and the longer term safety profile 
will become clearer with increasing use of B-cell-depleting therapies like ocrelizumab. Tables 2 and 3 
summarise the approach to adverse events and special prescribing circumstances. Italicised points 
denote personal practice, rather than established recommendations. 
The relatively favourable safety profile of rituximab is likely due to preservation of protective 
antibody production by CD20negative long-lived plasma cells. However, it remains uncertain 
whether long term humoral immunity results entirely from these self-sustaining cells or whether 
replenishment of plasma cells by memory B-cells is required. Several studies have reported 
secondary antibody deficiency complicating rituximab therapy—a risk that appears to increase with 
repeated courses and lower pretreatment levels of immunoglobulins.67 78–80 Not all patients with 
hypogammaglobulinaemia develop infections, but we recently reported a series of serious 
sinopulmonary infections associated with hypogammaglobulinaemia occurring in patients with 
NMOSD on long-term rituximab.81 All patients had prior exposure to immunosuppressant 
medications. This has led to changes in our practice, with greater focus on pretreatment 
vaccinations, B-cell monitoring to limit cumulative rituximab dose and targeted use of 
immunoglobulin replacement therapy to mitigate sinopulmonary infections in selected patients (see 
figure 4, table 3 and Box 1). 
 
Pregnancy and breast feeding 
Rituximab crosses the placenta after 20 weeks’ gestagestation. Although not known for certain, the 
existing evidence suggests that rituximab is possibly safe for use during early pregnancy (see table 
2).82 The prolonged B-cell-depleting effect (sometimes greater than the 40 weeks of gestation) can 
be used advantageously. For example, in planned pregnancies, rituximab could be given before 
conception and after delivery, sparing the gestating fetus from B-cell depletion. 
 
In relapsing conditions with high morbidity, such as NMOSD, the risk of relapse during protracted 
interruption of rituximab therapy for conception and pregnancy is a dilemma for many women. A 
recent expert review suggests that two doses of 1000 mg could be given as close as 1 month before 
planned conception in the hope that B-cell depletion will persist for the duration of pregnancy. They 
advise that rituximab could be resumed in the first week after delivery given the very high 
postpartum risk of NMOSD relapse.83 However, women should be counselled about the limited data 
on rituximab-exposed pregnancies.84 
 
 
 
 
 
 
Ocrelizumab 
While this is review is primarily intended to cover rituximab, it may be remiss not to discuss 
ocrelizumab, as this is the first anti-CD20 therapy to gain a licence (Food and Drug Administration, 
EMA) for a neurological indication (MS). Ocrelizumab has been in development for over a decade 
but progress in rheumatoid arthritis was halted in 2010 after data from multiple phase III trials 
suggested an excess of serious infections and a poor benefit-risk profile when combined with 
methotrexate. However, trials in MS continued and it was licensed in the USA in March 2017 and in 
Europe in January 2018. The European licence is for treating active relapsing MS and early primary 
progressive MS with imaging features of inflammatory activity. Recent phase III randomised 
controlled trials showed that ocrelizumab reduced annualised relapse rates versus interferon beta-
1a in relapsing MS, and reduced 12-week confirmed disability progression versus placebo in primary 
progressive MS.85 86 The trials used a fixed dosing schedule over 2 years of follow-up. The safety 
profile appeared favourable. Infusion reactions were frequent but rarely problematic. Upper 
respiratory tract infections were more common after ocrelizumab but there was no excess of serious 
or opportunistic infections. Ocrelizumab was associated with low total serum IgM in 16% of patients, 
but no increased infection risk was observed in these patients. There was no reduction in total 
serum IgG or disease-specific antibody titres over the 2-year follow-up period. An increased risk of 
malignancies (including breast cancer) was observed in the ocrelizumab trial arms but the incidence 
was within the 
background rate expected for an MS population.85 86 
Ocrelizumab has been licensed as a fixed six-monthly dosing regimen with no specific immune 
function monitoring, despite the fact that considerable interindividual variation is observed in time-
to-repopulation of B-cells following ocrelizumab.87 The experience of ocrelizumab in clinical trials 
may seem inconsistent with our and others’ real-world experience of rituximab, in which we have 
observed the coexistence of secondary antibody deficiency and increased rate of infections in 
patients with NMOSD on maintenance therapy.78–81 We postulate that this may relate to a degree 
of baseline immune dysfunction caused by prior immunosuppressive medication and a longer 
treatment duration than is recorded in the pivotal ocrelizumab studies. This echoes experience in 
vasculitis, where previous immunosuppressive therapy (particularly cyclophosphamide) has been 
identified as a risk factor for greater decline in immunoglobulin levels and more prolonged B-cell 
depletion after rituximab.25 88 In contrast, the vast majority of patients recruited to the MS 
ocrelizumab trials were treatment naïve or had used non-immunosuppressive disease-modified 
therapies. Safety information on ocrelizumab from postmarketing surveillance will be useful to 
further inform risk and to guide whether flexible dosing may become preferable in certain situations. 
Sequential treatment effects following high-efficacy disease-modified therapies are also yet to be 
explored. 
 
Conclusion 
Rituximab is a valuable treatment option for a variety of neuroinflammatory conditions. While there 
are no randomised controlled trials and questions remain about optimal dosing strategies, there is a 
growing body of evidence to support its use in specific situations. Overall, rituximab has an excellent 
safety profile, and relative to other immunomodulatory treatments, it may be an option for 
managing severe active diseases in pregnancy. However, neurologists need to be aware of specific 
management issues, including secondary antibody deficiency in patients requiring maintenance B-
cell depletion. Specific risk factors to consider include low pretreatment immunoglobulin levels, 
prior use of immunosuppressive drugs or a requirement for ongoing combination therapy. 
Newer and more costly B-cell-depleting therapies show additional promise in recent and ongoing 
trials but it remains to be seen if more effective and prolonged B-cell depletion will pose additional 
risks. Prospective registries with extended follow-up will be important in better defining the real-life 
risks and benefits for patients. 
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